Compare Stocks: FBIO, IKT, TTRX, and ZNTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.93 -1.7%	$3.07	$1.97 ▼ $4.53	$98.99M	1.21	693,324 shs	1.03 million shs
IKT Inhibikase Therapeutics	$2.41	$2.07	$1.33 ▼ $2.53	$336.28M	0.95	783,509 shs	227,865 shs
TTRX Turn Therapeutics	$9.57 -2.9%	$8.03	$2.57 ▼ $26.50	$293.71M	N/A	75,802 shs	98,233 shs
ZNTL Zentalis Pharmaceuticals	$3.56 -14.2%	$4.34	$1.21 ▼ $6.95	$297.44M	1.92	1.14 million shs	4.58 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+8.36%	+7.58%	-20.11%	+23.65%	+54.40%
IKT Inhibikase Therapeutics	+0.42%	0.00%	+16.99%	+39.31%	+240,999,900.00%
TTRX Turn Therapeutics	-6.45%	+2.60%	+2.28%	+143.46%	+985,999,900.00%
ZNTL Zentalis Pharmaceuticals	-3.26%	-17.00%	-13.00%	+2.47%	+178.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$2.93 -1.7%	$3.07	$1.97 ▼ $4.53	$98.99M	1.21	693,324 shs	1.03 million shs
IKT Inhibikase Therapeutics	$2.41	$2.07	$1.33 ▼ $2.53	$336.28M	0.95	783,509 shs	227,865 shs
TTRX Turn Therapeutics	$9.57 -2.9%	$8.03	$2.57 ▼ $26.50	$293.71M	N/A	75,802 shs	98,233 shs
ZNTL Zentalis Pharmaceuticals	$3.56 -14.2%	$4.34	$1.21 ▼ $6.95	$297.44M	1.92	1.14 million shs	4.58 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+8.36%	+7.58%	-20.11%	+23.65%	+54.40%
IKT Inhibikase Therapeutics	+0.42%	0.00%	+16.99%	+39.31%	+240,999,900.00%
TTRX Turn Therapeutics	-6.45%	+2.60%	+2.28%	+143.46%	+985,999,900.00%
ZNTL Zentalis Pharmaceuticals	-3.26%	-17.00%	-13.00%	+2.47%	+178.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	2.25	Hold	$17.00	480.20% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	124.07% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-16.41% Downside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	89.61% Upside

Current Analyst Ratings Breakdown

Latest FBIO, IKT, TTRX, and ZNTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TTRX Turn Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/13/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (D-)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/6/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$63.26M	1.54	N/A	N/A	$2.00 per share	1.47
IKT Inhibikase Therapeutics	$260K	1,293.43	N/A	N/A	$1.10 per share	2.19
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.02 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	3.78	N/A	N/A	$2.00 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	$6.82M	$3.17	1.11	N/A	N/A	163.32%	101.74%	46.34%	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	N/A

Latest FBIO, IKT, TTRX, and ZNTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A
5/14/2026	Q1 2026	FBIO Fortress Biotech	-$0.22	$2.82	+$3.04	$2.82	$16.34 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	0.18	2.86	2.77
IKT Inhibikase Therapeutics	N/A	15.82	30.14
TTRX Turn Therapeutics	8.83	1.19	2.23
ZNTL Zentalis Pharmaceuticals	N/A	4.82	6.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
IKT Inhibikase Therapeutics	3.81%
TTRX Turn Therapeutics	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	28.50%
IKT Inhibikase Therapeutics	7.10%
TTRX Turn Therapeutics	N/A
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	33.22 million	23.75 million	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

FBIO, IKT, TTRX, and ZNTL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14 at 9:16 AM | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14 at 9:16 AM | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13 at 10:23 PM | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13 at 4:01 PM | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11 at 7:41 AM | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Lowered to "Strong Sell" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 7, 2026 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

August 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 6, 2026 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

July 23, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

July 22, 2026 | marketbeat.com

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

July 20, 2026 | zacks.com

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Mizuho

July 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals Insider Trading Activity | NASDAQ:ZNTL | Benzinga

June 30, 2026 | benzinga.com

Zentalis Shareholders Back Directors, Auditors and Executive Pay

June 18, 2026 | tipranks.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, TTRX, and ZNTL Company Descriptions

Fortress Biotech NASDAQ:FBIO

$2.93 -0.05 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.01 (+0.31%)

As of 07:55 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Inhibikase Therapeutics NASDAQ:IKT

$2.41 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 07:34 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Turn Therapeutics NASDAQ:TTRX

$9.57 -0.29 (-2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$9.84 +0.27 (+2.77%)

As of 07:34 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.56 -0.59 (-14.22%)

Closing price 04:00 PM Eastern

Extended Trading

$3.58 +0.02 (+0.53%)

As of 07:56 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, IKT, TTRX, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, IKT, TTRX, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, IKT, TTRX, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, TTRX, and ZNTL Company Descriptions

Fortress Biotech NASDAQ:FBIO

Inhibikase Therapeutics NASDAQ:IKT

Turn Therapeutics NASDAQ:TTRX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBIO, IKT, TTRX, and ZNTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBIO, IKT, TTRX, and ZNTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBIO, IKT, TTRX, and ZNTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, IKT, TTRX, and ZNTL Company Descriptions

Fortress Biotech NASDAQ:FBIO

Inhibikase Therapeutics NASDAQ:IKT

Turn Therapeutics NASDAQ:TTRX

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools